Leflunomide 20mg tab (DrugBank: Leflunomide)
10 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
11 | Myasthenia | 0 |
40 | Takayasu arteritis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
53 | Sjogren syndrome | 0 |
66 | IgA nephropathy | 0 |
162 | Pemphigoid | 0 |
224 | Purpura nephritis | 0 |
271 | Ankylosing spondylitis | 0 |
300 | IgG4-related disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04022525 (ClinicalTrials.gov) | February 1, 2018 | 15/7/2019 | Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches | Assessment of Leflunomide Efficacy and Hepatotoxicity in Patients With Rheumatoid Arthritis Through Pharmacokinetic and Genetic Approaches | Rheumatoid Arthritis | Drug: Leflunomide 20Mg Tab | Assiut University | NULL | Completed | 18 Years | N/A | All | 80 | Egypt |